anti vegf ang2 nanobody bi 836880

Drug Overview

The anti-VEGF/Ang2 nanobody BI 836880 is an investigational drug designed to stop tumors from growing by cutting off their blood supply. Because it specifically targets and blocks proteins that cancer cells use to build new blood vessels, this medication is classified as a Targeted Therapy.

• Generic Name: BI 836880 (anti-VEGF/Ang2 bispecific nanobody)
• US Brand Names: None (Investigational drug)
• Drug Class: Bispecific Nanobody / Angiogenesis Inhibitor (Targeted Therapy)
• Route of Administration: Intravenous (IV) Infusion for cancer; Intravitreal injection (into the eye) for eye diseases.
• FDA Approval Status: Not FDA Approved. This medication is currently in clinical trials and is not yet available for public use outside of a research setting.
  
  Learn about the anti vegf ang2 nanobody bi 836880 in oncology. Trust our top-rated medical hospital for advanced patient care and support.

What Is It and How Does It Work? (Mechanism of Action)

To grow and spread, a tumor needs a constant supply of oxygen and nutrients. It gets this by creating its own network of blood vessels, a process called angiogenesis. Tumors release specific proteins to signal the body to build these blood vessels. Two of the most important signaling proteins are Vascular Endothelial Growth Factor (VEGF) and Angiopoietin-2 (Ang2).

BI 836880 works at the molecular level to stop this process:

1. Dual Targeting: BI 836880 is a “bispecific nanobody,” meaning it is engineered to bind to two different targets at the same time. It acts like a molecular sponge, soaking up both VEGF and Ang2 proteins in the bloodstream and the tumor area.
2. Blocking Receptors: By binding to VEGF and Ang2, the drug physically prevents these proteins from attaching to their matching receptors (VEGFR-2 and Tie-2) on the surface of blood vessel cells.
3. Stopping Blood Vessel Growth: Without the signals from VEGFR-2 and Tie-2, the blood vessels cannot sprout or remodel. This stops new blood vessels from forming around the tumor.
4. Starving the Tumor: By cutting off the blood supply, the tumor is starved of the oxygen and nutrients it needs to survive, which can slow down or stop its growth. Furthermore, blocking these proteins helps reverse the “shield” the tumor uses to hide from the immune system, making it easier for immune cells to attack the cancer.

FDA-Approved Clinical Indications

Because BI 836880 is an investigational drug, it does not currently have any FDA-approved indications. It is being studied in clinical trials for the following conditions:

Investigational Oncological Uses

• Advanced or Metastatic Solid Tumors
• Non-Small Cell Lung Cancer (NSCLC)
• Hepatocellular Carcinoma (Liver Cancer)
• Microsatellite Stable Colorectal Cancer (MSS CRC)
• Recurrent Glioblastoma (Brain Cancer)

Investigational Non-Oncological Uses

• Wet Age-related Macular Degeneration (wAMD) – An eye disease involving abnormal blood vessel growth.

Dosage and Administration Protocols

Note: As an experimental medication, there is no standard commercial dosage. The table below reflects the Recommended Phase 2 Dose (RP2D) established during recent clinical trials for oncology patients.

Clinical Efficacy and Research Results

Recent clinical studies (2020–2025) have focused on combining BI 836880 with Immunotherapy drugs (like the PD-1 inhibitor ezabenlimab) to see if they work better together.

• Overall Response: In a large Phase 1b trial involving over 230 patients with various advanced solid tumors, about 18.9% of patients saw their tumors shrink (Objective Response Rate).
• Specific Cancers: The drug combination showed the most promise in advanced liver cancer (Hepatocellular Carcinoma), where tumor shrinkage was seen in up to 40% of patients previously treated with other targeted therapies.
• Disease Control: In patients with advanced colorectal cancer, while tumor shrinkage was lower (about 7%), up to 50% of patients achieved “stable disease,” meaning their cancer stopped growing for a period of time.

While these numbers show that the drug has active cancer-fighting abilities, research is still ongoing to figure out which patients benefit the most from this specific combination.

Safety Profile and Side Effects

Because BI 836880 changes how blood vessels work, it can cause specific side effects related to blood pressure and bleeding.

Common Side Effects (>10%)

• Hypertension (High Blood Pressure): This is the most common side effect (affecting up to 58% of patients in some trials) because narrowing blood vessels increases blood pressure.
• Proteinuria: Protein leaking into the urine due to stress on the kidneys.
• Gastrointestinal Issues: Nausea, vomiting, and diarrhea.
• General Symptoms: Asthenia (weakness) and fatigue.

Serious Adverse Events

• Blood Clots: There is a risk of serious blood clots, including Pulmonary Embolism (a clot in the lungs), which was seen at very high experimental doses.
• Severe Bleeding (Hemorrhage): Drugs that block VEGF can interfere with the body’s ability to heal wounds and stop bleeding.

Black Box Warning

Because BI 836880 is not FDA-approved, it does not have an official Black Box Warning. However, all drugs in the VEGF-inhibitor class carry strict warnings for severe bleeding, gastrointestinal perforation (a hole in the stomach or intestine), and impaired wound healing.

Management Strategies

If a patient develops high blood pressure, doctors will usually prescribe standard blood pressure medications. If blood pressure becomes dangerously high or if there is too much protein in the urine, the infusion may be delayed or stopped. If severe bleeding occurs, treatment is halted immediately.

Research Areas: Connection to Immunotherapy and the Tumor Microenvironment

While BI 836880 is not directly a stem cell therapy, its role in tissue and blood vessel remodeling is highly relevant to modern cancer research. Tumors use the Angiopoietin-2 (Ang2) and VEGF pathways not just to build blood vessels, but to create a “wall” that keeps the body’s immune cells out. Current research shows that by blocking these pathways, BI 836880 normalizes the blood vessels and alters the tumor microenvironment. This makes the tumor vulnerable, allowing T-cells (the body’s natural cancer-fighting cells) to enter the tumor and destroy it. This is why BI 836880 is heavily researched in combination with immune checkpoint inhibitors.

Patient Management and Practical Recommendations

To keep patients safe during clinical trials, doctors follow strict monitoring rules.

Pre-Treatment Tests

• Blood Pressure Check: Must be well-controlled before starting treatment.
• Urinalysis: To check for protein in the urine (proteinuria).
• Blood Tests: Liver and kidney function panels, as well as blood clotting tests (PT/INR).

Precautions During Treatment

Patients who have recently had surgery, have unhealed wounds, or have a high risk of severe bleeding (like stomach ulcers) are generally not given this medication because it stops new blood vessels from helping wounds heal.

Do’s and Don’ts

• DO check your blood pressure daily at home and keep a log for your doctor.
• DO report any sudden chest pain, shortness of breath, or leg swelling immediately, as these could be signs of a blood clot.
• DON’T schedule any elective surgeries or dental procedures without telling your oncologist, as the drug affects wound healing.
• DON’T take aspirin or non-steroidal anti-inflammatory drugs (NSAIDs like ibuprofen) without your doctor’s approval, due to increased bleeding risks.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. BI 836880 is an investigational compound and is not approved by the FDA, EMA, or other global regulatory agencies for the treatment of any disease. Patients should always consult with a qualified, licensed healthcare professional or oncologist regarding treatment options, clinical trials, and medication safety. Do not disregard professional medical advice or delay seeking it because of information provided on this website.